Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ahad A. Sadiq"'
Autor:
Felipe Samaniego, Ahad A. Sadiq, Daruka Mahadevan, Michael Z. Koontz, Jose C. Villasboas, John M. Burke, Erin G Reid, Mohamad Cherry, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth H. Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Publikováno v:
Blood. 140:6498-6500
Autor:
Amikar Sehdev, Blase N. Polite, Hedy L. Kindler, Ahad Ali Sadiq, Jaclyn D Peterson, Smita S. Joshi, Mark M. Zalupski, Andrea Amico, Daniel V.T. Catenacci, Theodore Karrison, Vincent J. Picozzi, James L. Wade, Manish R. Sharma, Mark Kozloff, Robert de Wilton Marsh
Publikováno v:
Clinical Cancer Research. 26:18-24
Purpose: 5-Fluorouracil (5-FU)/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the a
Autor:
Bamidele A. Adesunloye, Ebenezer A. Kio, Shadia I. Jalal, Karen L. Reckamp, Michael L. Titzer, Robert M. Langdon, Robin Zon, Greg Andrew Durm, Goetz H. Kloecker, Sandra Althouse, Wael A. Harb, Ryan D. Gentzler, Radhika V. Walling, Ziyue Liu, Nasser H. Hanna, Salma K. Jabbour, Michael J. Williamson, Ahad Ali Sadiq
Publikováno v:
CancerReferences. 126(19)
BACKGROUND Five-year overall survival (OS) for patients with unresectable stage III non-small cell lung cancer (NSCLC) is poor. Until recently, a standard of care was concurrent chemoradiation alone. Patients with metastatic NSCLC treated with anti-p
Autor:
Ahad A. Sadiq, Patrick Wayne Cobb, Stephen B. Howell, Nasrin Rastgoo, Jose C. Villasboas, Jotin Marango, David Cosgrove, Rafael Bejar, Hongying Zhang, Donna Nguyen Haney, Victor M. Priego, Paul Conkling, Elizabeth Cull, William G. Rice, Erin Reid, Khalid Benbatoul, Yuying Jin, Jason M. Melear, M. Zach Koontz, Lindsey E. Roeker, Mohamad Cherry, Felipe Samaniego, Daruka Mahadevan, John M. Burke
Publikováno v:
Blood. 138:1355-1355
INTRODUCTION: Luxeptinib (CG-806) is a potent, non-covalent oral inhibitor of BTK and FLT3. It suppresses BCR signaling pathways (LYN, SYK, BTK, AKT, ERK) and other oncogenic pathways in cell lines and primary CLL cells, kills malignant B-cells insen
Autor:
Robert A. Kratzke, Marian G. Kratzke, Arpita De, Blake A. Jacobson, Joe Jay-Dixon, Manish R. Patel, Mark S. Peterson, Ahad A. Sadiq
Publikováno v:
Investigational New Drugs. 36:217-229
Deregulation of cap-dependent translation has been implicated in the malignant transformation of numerous human tissues. 4EGI-1, a novel small-molecule inhibitor of cap-dependent translation, disrupts formation of the eukaryotic initiation factor 4F
Autor:
Robert A. Kratzke, Joe Jay-Dixon, Jeremy Drees, Ahad A. Sadiq, Stephen J. Russell, Manish R. Patel, Blake A. Jacobson, Shaogeng Tang, Brent S. Sorenson
Publikováno v:
Oncotarget
Malignant mesothelioma has a poor prognosis for which there remains an urgent need for successful treatment approaches. Infection with the Edmonston vaccine strain (MV-Edm) derivative of measles virus results in lysis of cancer cells and has been tes
Autor:
Ryan D. Gentzler, Ahad Ali Sadiq, Goetz H. Kloecker, Robert M. Langdon, Shadia I. Jalal, Karen L. Reckamp, Sandra K. Althouse, Greg Andrew Durm, Salma K. Jabbour, Nikhil Shukla, Nasser H. Hanna, Bamidele Adesunloye, Robin Zon, William B. Fisher, Ebenezer A. Kio
Publikováno v:
Journal of Clinical Oncology. 38:9032-9032
9032 Background: Consolidation checkpoint inhibitor therapy (CPI) for up to 1 year following chemoradiation (CRT) is a current standard of care for pts with inoperable stage III NSCLC. However, some pts are not able to complete 1 year of CPI due to i
Autor:
Saritha C. Thumma, Joseph Jay-Dixon, Manish R. Patel, Jeremy R. Graff, Bruce W. Konicek, Robert A. Kratzke, Ahad A. Sadiq, Arnab De, Blake A. Jacobson, Michael J Franklin
Publikováno v:
Cancer Gene Therapy. 22:396-401
Elevated levels of eukaryotic translation initiation factor 4E (eIF4E) enhance translation of many malignancy-related proteins, such as vascular endothelial growth factor (VEGF), c-Myc and osteopontin. In non-small-cell lung cancer (NSCLC), levels of
Autor:
Robin Zon, Ebenezer A. Kio, Karen L. Reckamp, Goetz H. Kloecker, Nasser H. Hanna, Sandra K. Althouse, M. Williamson, C. Yeon, B. Adesunloye, Salma K. Jabbour, G. Durm, Ryan D. Gentzler, Shadia I. Jalal, Wael A. Harb, Marianna Koczywas, Radhika Walling, Robert M. Langdon, Ahad Ali Sadiq
Publikováno v:
Journal of Thoracic Oncology. 14:S627
Autor:
Ahad Ali Sadiq, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 31:1089-1096
Lung cancer is a heterogeneous group of disorders that is now being subdivided into molecular subtypes with dedicated targeted therapies. The MET receptor tyrosine kinase has been identified as aberrantly overexpressed, potentially having activating